Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Contributed by: Business Wire

Logo

Tags

Health

FDA

Consumer

Children

General Health

Pharmaceutical

Biotechnology

Ataxia Telangiectasia

More Like This

PR Newswire associated0

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

PR Newswire associated0

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease